Specialty code 1835P2201X · Charlotte, NC
NPI
1992280721
Since 2018
Specialty
Specialty code 1835P2201X
Code 1835P2201X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
200 Hawthorne Ln
Charlotte, NC, 28204
Phone (704) 384-4000
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$1.5M
1,463 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Daniel C Szabat prescribed most often to Medicare patients was Jardiance (Empagliflozin), with 335 prescriptions and refills. In total Daniel C Szabat wrote 1,463 Medicare prescriptions that cost $1.5M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-09-23.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Jardiance Empagliflozin | 335 | 817 | 140 | $473K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 134 | 324 | 56 | $28K |
| Ozempic Semaglutide | 85 | 155 | 54 | $142K |
| Humalog Kwikpen U-100 Insulin Lispro | 67 | 155 | 22 | $24K |
| Forteo Teriparatide | 62 | 62 | Under 11 | $256K |
| Tradjenta Linagliptin | 54 | 112 | 21 | $55K |
| Novolog Flexpen Insulin Aspart | 49 | 115 | 21 | $22K |
| Techlite Pen Needle Pen Needle, Diabetic | 47 | 103 | 22 | $1,947 |
| Farxiga Dapagliflozin Propanediol | 43 | 123 | 23 | $67K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 42 | 110 | 26 | $5,376 |
| Januvia Sitagliptin Phosphate | 39 | 97 | 14 | $51K |
| Victoza 3-Pak Liraglutide | 33 | 46 | 13 | $32K |
| Ultra-Fine Mini Pen Needle Pen Needle, Diabetic | 32 | 86 | 11 | $2,430 |
| Trulicity Dulaglutide | 32 | 43 | 15 | $41K |
| Mounjaro Tirzepatide | 31 | 37 | 15 | $38K |
Brand drugs: 1,203 claims; generic drugs: 73 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Daniel C Szabat were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.